CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling

S. Ventura, D. N T Aryee, F. Felicetti, A. de Feo, C. Mancarella, M. C. Manara, P. Picci, M. P. Colombo, H. Kovar, A. Carè, K. Scotlandi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-κB (NF-κB) signaling is inhibited and the neural differentiation program is re-established. NF-κB inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-κB signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-κB signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.Oncogene advance online publication, 30 November 2015; doi:10.1038/onc.2015.463.

Original languageEnglish
JournalOncogene
DOIs
Publication statusAccepted/In press - Nov 30 2015

Fingerprint

Ewing's Sarcoma
Exosomes
Oncogenes
Sarcoma
Small Interfering RNA
Publications
Neoplasms
Carcinogenesis
Population

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling. / Ventura, S.; Aryee, D. N T; Felicetti, F.; de Feo, A.; Mancarella, C.; Manara, M. C.; Picci, P.; Colombo, M. P.; Kovar, H.; Carè, A.; Scotlandi, K.

In: Oncogene, 30.11.2015.

Research output: Contribution to journalArticle

@article{f8faf47701044da792add6d0de23e3df,
title = "CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling",
abstract = "Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-κB (NF-κB) signaling is inhibited and the neural differentiation program is re-established. NF-κB inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-κB signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-κB signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.Oncogene advance online publication, 30 November 2015; doi:10.1038/onc.2015.463.",
author = "S. Ventura and Aryee, {D. N T} and F. Felicetti and {de Feo}, A. and C. Mancarella and Manara, {M. C.} and P. Picci and Colombo, {M. P.} and H. Kovar and A. Car{\`e} and K. Scotlandi",
year = "2015",
month = "11",
day = "30",
doi = "10.1038/onc.2015.463",
language = "English",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling

AU - Ventura, S.

AU - Aryee, D. N T

AU - Felicetti, F.

AU - de Feo, A.

AU - Mancarella, C.

AU - Manara, M. C.

AU - Picci, P.

AU - Colombo, M. P.

AU - Kovar, H.

AU - Carè, A.

AU - Scotlandi, K.

PY - 2015/11/30

Y1 - 2015/11/30

N2 - Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-κB (NF-κB) signaling is inhibited and the neural differentiation program is re-established. NF-κB inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-κB signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-κB signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.Oncogene advance online publication, 30 November 2015; doi:10.1038/onc.2015.463.

AB - Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-κB (NF-κB) signaling is inhibited and the neural differentiation program is re-established. NF-κB inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-κB signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-κB signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.Oncogene advance online publication, 30 November 2015; doi:10.1038/onc.2015.463.

UR - http://www.scopus.com/inward/record.url?scp=84955325978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955325978&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.463

DO - 10.1038/onc.2015.463

M3 - Article

AN - SCOPUS:84955325978

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -